

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



*(Incorporated in the Cayman Islands as an exempted company with limited liability)*

**(Stock code: 1873)**

## **COMPLETION OF THE ACQUISITION OF REMAINING INTEREST IN LANGHUA PHARMACEUTICAL AND DISCHARGE OF IRREVOCABLE BANK GUARANTEE**

Reference is made to the announcement (the “**Exercise of Right Announcement**”) of Viva Biotech Holdings (the “**Company**”) dated September 13, 2023 relating to the Vendors’ exercise of the Vendors’ Qualified Right of Sale to transfer the remaining 20% equity interest in Langhua Pharmaceutical to Weizongchen Pharmaceutical, an indirect wholly-owned subsidiary of the Company. Unless otherwise stated, terms used in this announcement shall have the same meanings as defined in the Exercise of Right Announcement.

The Board is pleased to announce that on September 21, 2023, all conditions of the Equity Transfer Agreement has been met and completion has taken place. Upon completion of the transaction, Langhua Pharmaceutical has become an indirect wholly-owned subsidiary of the Company.

Pursuant to the agreement between the Group and the Vendors, Viva Biotech Shanghai has provided an irrevocable bank guarantee of RMB640 million to secure the performance of the Vendors’ Qualified Right of Sale, and upon completion of the acquisition, the irrevocable bank guarantee and the Group’s deposit pledge to the bank in connection with the irrevocable guarantee has been discharged in full. Upon the discharge, previously pledged deposit may be freely utilized by the Group, and the Company intends to utilize the funds for uses including supplementing the Group’s general working capital, repayment of existing indebtedness and if suitable opportunities arises, repurchase ordinary shares (the “**Shares**”) under the general mandate (the “**Repurchase Mandate**”) to repurchase Shares as granted by the shareholders of the Company on June 30, 2023 as it considers fit.

Any proposed Share repurchase will be conducted in compliance with the memorandum and articles of association of the Company, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), the Codes on Takeovers and Mergers and Share Buy-backs, the Companies Law of the Cayman Islands and all applicable consents, laws and regulations to which the Company is subject to. Any proposed Share repurchase shall also not result in the number of the Shares held by the public falling below the relevant minimum percentage prescribed by the Listing Rules.

Shareholders of the Company and potential investors should note that, as at the date of this announcement, the Company has not repurchased any Shares. The exercise of the Repurchase Mandate will be subject to market conditions and will be at the absolute discretion of the Board. The Company may or may not make share repurchases. There is no assurance of the timing, quantity or price of any Share repurchases or whether or not the Company will make any repurchases.

**Shareholders of the Company and potential investors should exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Viva Biotech Holdings**  
**Mao Chen Cheney**  
*Chairman and Chief Executive Officer*

Hong Kong, September 21, 2023

*As at the date of this announcement, the Board comprises three Executive Directors, namely, Mr. Mao Chen Cheney (Chairman), Mr. WU Ying and Mr. Ren Delin; a Non-executive Director, namely, Mr. WU Yuting; and three Independent Non-executive Directors, namely, Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang.*